Fighting for Europe's Future
Jean-Francois Dehecq, sanofi-aventis, France, noted that innovation is founded in strong science and research, is critical for success and competitiveness, and contributes to the health of patients and wealth of society.
Jean-Francoise Dehecq, sanofi-aventis
Jean-Francois Dehecq, sanofi-aventis, France, noted that innovation is founded in strong science and research, is critical for success and competitiveness, and contributes to the health of patients and wealth of society.
Dehecq pointed out that everyone agrees changes need to be made; for Europe has become dependent on the United States for the development of new products--which is quite different from the state of European pharmaceuticals in the early 1990s when Europe led the United States and Japan in R&D expenditure. In order to become a leader again, Dehecq stressed that Europe needs to defend the industry or it will lose it.
So, what is the problem? According to Dehecq, there are two problems: Europe is not working as a single market and it perceives innovation as a cost and not an achievement worthy of reward. To change the current state of pharmaceutical R&D in Europe and secure the future of its pharmaceutical innovation, Dehecq outlined a number of necessary changes, including the need to focus on value and not cost, the need to set up sustainable funding mechanisms (e.g., increased patient participation in health care costs), and the need to support science and strengthen the science base (e.g., funding and improved relationships with academia, regulators, and patients).
Dehecq wrapped up his presentation by concluding that governments have a role to play, one that includes rewarding innovation and regulating less, which he noted is the biggest threat to Europe's future. He also stressed the need for the different cultures in Europe, where "we are fighting for the future of this industry."
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
